Compare PIPR & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PIPR | BLTE |
|---|---|---|
| Founded | 1895 | 2018 |
| Country | United States | United States |
| Employees | N/A | 41 |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 6.0B |
| IPO Year | 2003 | 2021 |
| Metric | PIPR | BLTE |
|---|---|---|
| Price | $75.60 | $147.02 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $91.38 | ★ $198.00 |
| AVG Volume (30 Days) | ★ 484.6K | 237.7K |
| Earning Date | 05-01-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.26% | N/A |
| EPS Growth | ★ 54.49 | N/A |
| EPS | ★ 0.92 | N/A |
| Revenue | ★ $1,904,217,000.00 | N/A |
| Revenue This Year | $12.30 | N/A |
| Revenue Next Year | $13.55 | $492.11 |
| P/E Ratio | $84.50 | ★ N/A |
| Revenue Growth | ★ 24.33 | N/A |
| 52 Week Low | $72.48 | $56.68 |
| 52 Week High | $380.26 | $200.00 |
| Indicator | PIPR | BLTE |
|---|---|---|
| Relative Strength Index (RSI) | 33.34 | 51.88 |
| Support Level | $73.54 | $132.50 |
| Resistance Level | $82.17 | $151.41 |
| Average True Range (ATR) | 2.49 | 6.74 |
| MACD | 0.52 | 1.51 |
| Stochastic Oscillator | 8.65 | 70.76 |
Piper Sandler Cos is an investment bank and institutional securities firm, serving the needs of corporations, private equity groups, public entities, non-profit entities and institutional investors in the United States (U.S.) and internationally. The company provides a broad set of products and services, including financial advisory services; equity and debt capital markets products; public finance services; institutional brokerage services; fundamental equity and macro research services; fixed income services; and alternative asset management strategies. It generates maximum revenue from Advisory services followed by Equity financing.
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.